Although the relative contributions of increased GR dimerization and decreased plasma clearance to the protection against SIRS is not clear, our screening pipeline identified two compounds that are promising therapeutic candidates meriting further attention in the context of acute inflammation. This evidence concerns the gene NR3C1 and systemic inflammatory response syndrome.